NCT06561087招募中2 期
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Safety and AdverseEevents (AEs)
研究概览
简要总结
To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
详细描述
Primary Objectives:
To assess the oral cancer free survival following intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
Secondary Objectives:
To describe the objective response rate (ORR) in index lesions following intralesional injections of nivolumab in patients with high-risk oral premalignant lesions, according to modified World Health Organization (WHO) criteria.
To describe the pathologic complete response (CR) rate in index lesions following intralesional injections of nivolumab in patients with high-risk oral premalignant lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of a treatment naïve, biopsy proven, intraoral premalignant lesion visible from oral cavity.
- •Be willing and able to provide written informed consent for the trial. In the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an ICD in their language, will be utilized and completed in accordance with the MDACC "Policy For Consenting Non-English Speaking Participants."
- •Be >/= 18 years of age on day of signing informed consent.
- •Be willing to provide tissue, either archive or from a newly obtained oral biopsy.
- •Have a performance status of 0-2 on the ECOG Performance Scale.
- •Demonstrate adequate organ function as defined in Table 1
- •Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of study therapy through 120 days after the last dose of Nivolumab. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
排除标准
- •Is currently participating and receiving study therapy with potential anti-neoplastic activity or has participated in a study of an investigational agent and received study therapy with potential anti-neoplastic activity within 4 weeks of the first dose of treatment.
- •Has a known history of active TB (Bacillus Tuberculosis)
- •Hypersensitivity to nivolumab or any of its excipients.
- •Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 2 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 2 or at baseline) from adverse events due to a previously administered agent.
- •Has a known additional malignancy that is progressing or requires active treatment other than adjuvant hormonal therapy. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin or in situ cervical cancer.
- •Has known history of, or any evidence of active, non-infectious pneumonitis.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of treatment with nivolumab, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •Has received a live vaccine within 30 days of planned start of study therapy.
- •Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
研究组 & 干预措施
Nivolumab/Placebo
Experimental
Participants will be screened for LOH and randomly assigned to trial
干预措施: Nivolumab (Drug)
结局指标
主要结局
Safety and AdverseEevents (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsMesothelioma, MalignantNCT05136677Bristol-Myers Squibb102
已完成
2 期
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)Pan TumorNCT03668119Bristol-Myers Squibb212
已完成
1 期
Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaHodgkin LymphomaNCT03343665St. Petersburg State Pavlov Medical University30
终止
2 期
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaLocally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular CarcinomaNCT05199285Academic and Community Cancer Research United15
已完成
2 期
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerNasopharyngeal Nonkeratinizing CarcinomaRecurrent Nasopharynx CarcinomaStage III Nasopharyngeal Carcinoma AJCC v7Stage IV Nasopharyngeal Carcinoma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7Stage IVC Nasopharyngeal Carcinoma AJCC v7NCT02339558National Cancer Institute (NCI)45